WIIM

X Financial shares are trading higher after the company reported Q1 EPS and sales results were higher year over year. The company also raised Q2 guidance for loan facilitations.

<a href="https://www.prnewswire.com/news-releases/lumen-bioscience-and-novo-nordisk-enter-into-research-collaboration-to-explore-novel-strategies-to-deliver-oral-biologics-for-cardiometabolic-disease-301313338.html" title="https://www.prnewswire.com/news-releases/lumen-bioscience-and-novo-nordisk-enter-into-research-collaboration-to-explore-novel-strategies-to-deliver-oral-biologics-for-cardiometabolic-disease-301313338.html">https://www.prnewswire.com/news-releases/lumen-bioscience-and-novo-nordisk-enter-into-research-collaboration-to-explore-novel-strategies-to-deliver-oral-biologics-for-cardiometabolic-disease-301313338.html</a>

Biotech

General

Lumen Bioscience And Novo Nordisk Enter Research Collaboration To Explore Novel Strategies To Deliver Oral Biologics For Cardiometabolic Disease; Financial Details Not Disclosed

Clever Leaves Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLVR#NASDAQ">CLVR</a>, CLVRW)))) (&quot;Clever Leaves&quot; or the &quot;Company&quot;),&nbsp;a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced it has entered into an active pharmaceutical ingredient (&quot;API&quot;) supply agreement with CBD Life Holding SAPI de CV (&quot;CBD Life&quot;), an emerging leader in the Mexican cannabis industry which offers a line of CBD Wellness and consumer products and medical cannabis products which are under development. Under the agreement, Clever Leaves will act as the API supplier for the development and manufacture of CBD Life&#39;s medical cannabis products. Commencing with CBD isolate, Clever Leaves aims to be the ongoing supplier of the required APIs for CBD Life&#39;s product manufacturing purposes. 
&nbsp;
The partnership is Clever Leaves&#39; first commercial agreement in the Mexican market, and it comes shortly after regulations were fully approved in the country, providing a strategic growth opportunity in one of the world&#39;s largest pharmaceutical markets.
CBD Life has significant distribution in Mexico, with their products available in more than 18,000 points of sale. The company has established itself as an early-mover when it comes to providing cannabis-based products to the Mexican market. It also has formed strategic alliances with some of Mexico&#39;s largest media groups and is the first cannabis company to launch a nationwide advertising campaign for non-psychoactive cannabinoid-based consumer products.
&quot;As a multinational cannabis operator with substantial operations in Latin America, it has always been one of our top goals to identify leaders in the region and build long-lasting commercial relationships,&quot; said Kyle Detwiler, CEO of Clever Leaves. &quot;CBD Life&#39;s brand positioning and local exposure are attractive, but it&#39;s their commitment to high-quality, pharmaceutical-grade medical cannabis products that makes this an ideal partnership.&quot;
CBD Life&#39;s current product line is comprised of topicals (including the traditional Hispanic household brand &quot;Mariguanol&quot;), beverages, and food supplements infused with hemp-derived CBD. With a team with more than 40 years of experience in brand building and pharmaceutical distribution, CBD Life is strongly positioned to develop and market safe and innovative cannabis pharmaceutical solutions.
&quot;We feel very fortunate to have the opportunity to work with Clever Leaves on our mission to develop safe and accessible pharmaceutical-grade cannabis medications of the highest quality. Our partnership will further propel our domestic and international expansion efforts thanks to their unmatched expertise and certifications that meet the highest standards and regulatory compliance equivalencies in most countries,&quot; said Janko Ruiz de Chavez, COO and co-founder of CBD Life.
According to a recent report from Prohibition Partners for Latin America and the Caribbean (2020), the medical cannabis market in Mexico could be worth 60 million USD by 2024. The recent regulatory changes that allow for the production and commercialization of medical cannabis, as well as stringent requirements for product commercialization, makes Clever Leaves, who produces pharmaceutical grade, EU GMP-certified cannabis, an ideal partner for companies wanting to enter the medical cannabis space in an effective, agile, and compliant way.

Cannabis

Markets

CLVR

Clever Leaves Announces Supply Agreement With CBD Life Holding To Act As API Supplier For Development And Manufacture Of CBD Life's Medical Cannabis Products; Terms Not Disclosed

News

VTGN

VistaGen Therapeutics Will Join Russell 2000 Index, Effective Jun. 28

ECOR

electroCore Reports Will Join Russell Microcap Index, Effective Jun. 28

Contracts

TSX:LPEN

Loop Energy Reports Order Of Co.'s S300 Fuel Cell Module To Mobility & Innovation To Fuel Electric Powertrain Of New 8-Meter Transit Bus, Sees $1.8M In Fuel Cell Shipments To M&I Over Next 2.5 Years

&nbsp;
<h3>Gainers</h3>
<ul>
<li>SPI Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPI#NASDAQ">SPI</a>) stock moved upwards by 30.94% to $8.59 during Wednesday&#39;s pre-market session. The company&#39;s market cap stands at $204.9 million.</li>
<li>Net Element (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NETE#NASDAQ">NETE</a>) shares increased by 4.01% to $11.65. The company&#39;s market cap stands at $60.6 million.</li>
<li>Infobird Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) stock moved upwards by 3.1% to $3.98.</li>
<li>WISeKey Intl Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) stock increased by 2.76% to $8.17. The market value of their outstanding shares is at $162.9 million.</li>
<li>Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) shares increased by 2.75% to $48.11. The market value of their outstanding shares is at $7.8 billion.</li>
<li>Limelight Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LLNW#NASDAQ">LLNW</a>) shares moved upwards by 2.4% to $3.4. The company&#39;s market cap stands at $427.3 million.</li>
</ul>
&nbsp;
&nbsp;
<h3>Losers</h3>
&nbsp;
<ul>
<li>ALFI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALF#NASDAQ">ALF</a>) shares declined by 13.49% to $6.03 during Wednesday&#39;s pre-market session.</li>
<li>MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) stock decreased by 8.11% to $23.57. The company&#39;s market cap stands at $1.0 billion.</li>
<li>Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) shares declined by 5.17% to $77.42. The company&#39;s market cap stands at $223.2 billion. The company&#39;s, Q4 earnings came out yesterday.</li>
<li>Bit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) stock decreased by 4.81% to $8.2. The company&#39;s market cap stands at $418.7 million.</li>
<li>Nxt-ID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTD#NASDAQ">NXTD</a>) stock fell 3.78% to $1.02. The company&#39;s market cap stands at $54.3 million.</li>
<li>Marathon Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) stock declined by 3.62% to $29.56. The company&#39;s market cap stands at $2.9 billion.</li>
</ul>
&nbsp;
&nbsp;

Pre-Market Outlook

Movers

ASAN

BTBT

IFBD

LLNW

MARA

NETE

NXTD

ORCL

WKEY

12 Information Technology Stocks Moving In Wednesday's Pre-Market Session

FTHM

Fathom Holdings To Acquire Epic Realty; Terms Not Disclosed

Baird analyst Mircea Dobre maintains Helios Technologies (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hlio#NASDAQ">HLIO</a>) with a Outperform and raises the price target from $89 to $94.Baird analyst Mircea Dobre maintains Helios Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NASDAQ">HLIO</a>) with a Outperform and raises the price target from $89 to $94.

Price Target

Analyst Ratings

HLIO

Baird Maintains Outperform on Helios Technologies, Raises Price Target to $94

Piper Sandler analyst Rob Owens maintains Palo Alto Networks (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/panw#NYSE">PANW</a>) with a Overweight and raises the price target from $425 to $450.Piper Sandler analyst Rob Owens maintains Palo Alto Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NYSE">PANW</a>) with a Overweight and raises the price target from $425 to $450.

PANW

Piper Sandler Maintains Overweight on Palo Alto Networks, Raises Price Target to $450

JP Morgan analyst Mark Murphy maintains Oracle (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/orcl#NYSE">ORCL</a>) with a Overweight and raises the price target from $73 to $77.JP Morgan analyst Mark Murphy maintains Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) with a Overweight and raises the price target from $73 to $77.

JP Morgan Maintains Overweight on Oracle, Raises Price Target to $77

&nbsp;
<h3>Gainers</h3>
<ul>
<li>Kindred Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIN#NASDAQ">KIN</a>) shares moved upwards by 45.26% to $9.21 during Wednesday&#39;s pre-market session. The market value of their outstanding shares is at $416.9 million.</li>
<li>Catabasis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATB#NASDAQ">CATB</a>) stock increased by 16.17% to $2.37. The market value of their outstanding shares is at $182.3 million.</li>
<li>MannKind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) shares increased by 10.0% to $4.51. The company&#39;s market cap stands at $1.1 billion.</li>
<li>Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) shares moved upwards by 9.48% to $5.31. The company&#39;s market cap stands at $112.5 million.</li>
<li>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) shares rose 7.36% to $22.0. The company&#39;s market cap stands at $1.3 billion.</li>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) stock increased by 6.87% to $17.1.</li>
</ul>
&nbsp;
&nbsp;
<h3>Losers</h3>
&nbsp;
<ul>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) stock fell 10.58% to $3.72 during Wednesday&#39;s pre-market session. The company&#39;s market cap stands at $214.1 million.</li>
<li>GBS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBS#NASDAQ">GBS</a>) shares decreased by 5.97% to $4.1.</li>
<li>Fusion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUSN#NASDAQ">FUSN</a>) stock declined by 5.92% to $9.07. The market value of their outstanding shares is at $385.0 million.</li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares decreased by 5.09% to $33.4. The market value of their outstanding shares is at $835.3 million.</li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares decreased by 4.69% to $178.3. The market value of their outstanding shares is at $13.2 billion.</li>
<li>OpGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>) stock fell 4.65% to $2.26. The company&#39;s market cap stands at $86.4 million.</li>
</ul>
&nbsp;
&nbsp;

APRE

CATB

CLSD

FUSN

MGNX

MNKD

NVAX

OPGN

RAPT

VERA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BCTX

BriaCell Therapeutics Announces It Is Expanding Breast Cancer Platform Into Prostate, Melanoma And Lung Cancers

&nbsp;
<h3>Gainers</h3>
<ul>
<li>Forward Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORD#NASDAQ">FORD</a>) shares moved upwards by 20.14% to $3.28 during Wednesday&#39;s pre-market session. The market value of their outstanding shares is at $32.6 million.</li>
<li>Ever-Glory Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVK#NASDAQ">EVK</a>) shares moved upwards by 9.02% to $2.9. The market value of their outstanding shares is at $42.9 million.</li>
<li>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) shares increased by 6.79% to $2.2. The market value of their outstanding shares is at $42.5 million.</li>
<li>ZHONGCHAO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) shares moved upwards by 4.54% to $1.84. The market value of their outstanding shares is at $43.3 million.</li>
<li>Waitr Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTRH#NASDAQ">WTRH</a>) stock rose 3.36% to $2.15. The company&#39;s market cap stands at $248.0 million.</li>
<li>Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) stock moved upwards by 2.54% to $22.99. The company&#39;s market cap stands at $1.1 billion.</li>
</ul>
&nbsp;
&nbsp;
<h3>Losers</h3>
&nbsp;
<ul>
<li>Blue Apron Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APRN#NYSE">APRN</a>) stock fell 20.44% to $4.4 during Wednesday&#39;s pre-market session. The company&#39;s market cap stands at $79.4 million.</li>
<li>TAL Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) stock decreased by 9.88% to $26.0. The company&#39;s market cap stands at $16.7 billion.</li>
<li>New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) stock declined by 8.18% to $8.76. The market value of their outstanding shares is at $14.9 billion.</li>
<li>Gaotu Techedu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) shares decreased by 7.28% to $14.53.</li>
<li>17 Education &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YQ#NASDAQ">YQ</a>) stock declined by 5.87% to $4.17. The company&#39;s market cap stands at $804.1 million.</li>
<li>Onion Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OG#NYSE">OG</a>) stock declined by 4.37% to $4.6. As per the news, the Q1 earnings report came out 4 days ago.</li>
</ul>
&nbsp;
&nbsp;

APRN

New Oriental Education & Technology Group

FNKO

FORD

GSX Techedu Inc. American Depositary Shares

GOTU

WTRH

XELB

ZCMD

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

SLGG

Super League Gaming To Join Russell Microcap Index, Effective Jun. 28

&nbsp;
<h3>Gainers</h3>
<ul>
<li>Super League Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGG#NASDAQ">SLGG</a>) stock rose 4.24% to $5.89 during Wednesday&#39;s pre-market session. The company&#39;s market cap stands at $210.3 million.</li>
<li>Orbsat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSAT#NASDAQ">OSAT</a>) shares moved upwards by 3.8% to $5.86. The company&#39;s market cap stands at $29.5 million.</li>
<li>LiveXLive Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVX#NASDAQ">LIVX</a>) shares moved upwards by 3.12% to $4.95. The market value of their outstanding shares is at $373.6 million.</li>
<li>trivago (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVG#NASDAQ">TRVG</a>) stock increased by 2.5% to $3.68. The market value of their outstanding shares is at $1.3 billion.</li>
<li>Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) stock rose 2.43% to $8.85. The market value of their outstanding shares is at $67.2 million.</li>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) stock increased by 2.18% to $1.87. The market value of their outstanding shares is at $25.1 million.</li>
</ul>
&nbsp;
&nbsp;
<h3>Losers</h3>
&nbsp;
<ul>
<li>Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONE#NASDAQ">UONE</a>) shares declined by 5.08% to $17.4 during Wednesday&#39;s pre-market session. The company&#39;s market cap stands at $875.7 million.</li>
<li>The9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCTY#NASDAQ">NCTY</a>) shares declined by 4.84% to $17.7. The company&#39;s market cap stands at $287.3 million.</li>
<li>MediaCo Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDIA#NASDAQ">MDIA</a>) shares declined by 3.95% to $4.87. The market value of their outstanding shares is at $38.2 million.</li>
</ul>
&nbsp;
&nbsp;

DLPN

IPDN

LIVX

MDIA

NCTY

OSAT

TRVG

UONE

9 Communication Services Stocks Moving In Wednesday's Pre-Market Session

<a href="https://www.globenewswire.com/Tracker?data=KDWpkvPoxZHoKzKjhFoZEYoEDU1gEylZbsH1zyw5sfhlBDAb9rAD-7LEFwLf3j8OHPN4KQwDtrTxEYG3uY-RbNz5akBVc9oXzXWTjMZuIQA=" target="_blank">Motus GI Holdings, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOTS#NASDAQ">MOTS</a>) (&quot;Motus GI&quot; or the &quot;Company&quot;), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today enrollment of the first patients in the European Union (EU) study of the Pure-Vu System, which is evaluating the clinical outcomes in patients with a history of poor bowel preparation using a low volume preparation with limited diet restrictions and the Pure-Vu System.
&ldquo;We are excited to initiate this study assessing the ability of the Pure-Vu System to help patients that have a history of poor preparation that has caused failed and repeated procedures. If this study is successful, we believe it could lead the way for our Pure-Vu System to change the management of patients who struggle to get an adequately prepped colon due to their age or medical need and historically have been unable to receive a proper examination. This study is the first to target this high need outpatient population, where we believe reducing the dependency on pre-procedural preparation to facilitate a quality exam is critically important,&rdquo; stated Tim Moran, Chief Executive Officer of Motus GI. &ldquo;We believe there is a large potential commercial market opportunity for the Pure-Vu System in the EU. According to iData Research Inc., there were approximately six million colonoscopies conducted in the EU during 2019, making it one of our largest addressable markets. We continue to evaluate potential partnership agreements that could best support our success in the EU, while also complementing our commercial activities in the U.S.&rdquo;
&ldquo;Advancing this study will allow us to further evaluate the potential for the Pure-Vu System to provide patients that struggle with bowel preparation a better solution than a cycle of repeat procedures with arduous preparation regimes to try and get a quality exam, in order to reduce the patients&rsquo; risk of colorectal cancer is an important medical need. Also, I believe getting these patients on a normal schedule, would not only improve their quality of life but also reduce the burden to the healthcare system by avoiding the cycle of early repeat procedures,&rdquo; commented Peter D. Siersema, MD, PhD, Professor of Endoscopic Gastrointestinal Oncology at the Radboud University Medical Center, Nijmegen, The Netherlands, and Medical Advisor to Motus GI.
The EU study will enroll approximately 44 patients who have a history of poor bowel preparation and are scheduled for either screening, diagnostic, or surveillance colonoscopy across two sites, including the Radboud University Medical Center (Netherlands) and the University Medical Center Mainz (Germany). The patients will undergo a low volume bowel preparation, with just 2x150ml picoprep. The patients will also be allowed to eat a low fiber diet for two days prior to the colonoscopy as opposed to the typical clear liquid diet the day before a colonoscopy. The patients will then receive intra-procedural bowel cleansing with the Pure-Vu System. The primary endpoint for the study is improvement of the bowel preparation from baseline to post procedure as assessed by the Boston Bowel Preparation Scale (BBPS), which assesses the cleanliness of each of the three segments of the colon on a zero to three scale and requires a minimum score of two or better per segment to be considered adequately prepped. The study will also look at key clinical endpoints related to the quality of the examination including detection of critical pathology in the colon.

MOTS

Motus GI Holdings Reports First Patients Enrolled In EU Feasibility Study Of Its Pure-Vu System As New Method For Bowel Cleansing In Patients With History Of Poor Bowel Preparation

Dovetail Genomics, the industry leader in advanced proximity ligation genomic solutions,&nbsp;today announced availability&nbsp;of its new line of capture Hi-C&nbsp;technology.&nbsp;The flagship products include two targeted enrichment&nbsp;panels, the Dovetail&reg;&nbsp;Human&nbsp;Pan Promoter Enrichment Kit,&nbsp;and the Dovetail&reg;&nbsp;Mouse&nbsp;Pan Promoter Enrichment Kit,&nbsp;enabling the&nbsp;interrogation of chromatin topology surrounding 80,000 coding and non-coding gene promoters&nbsp;for&nbsp;human and mouse samples&nbsp;respectively.&nbsp;Dovetail&#39;s&nbsp;solution&nbsp;incorporates&nbsp;Twist Bioscience&#39;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) proprietary&nbsp;targeted enrichment technology&nbsp;and is matched with&nbsp;Dovetail&#39;s&nbsp;unique&nbsp;Micro-C and&nbsp;Omni-C&reg;&nbsp;Assays, each of which utilize sequence-independent nucleases for superior coverage compared to restriction enzyme-based Hi-C methodologies. 
Genome-wide Hi-C studies have been highly informative&nbsp;in defining the&nbsp;critical relationship between chromosome architecture and gene expression.&nbsp;However, the sequencing&nbsp;depth&nbsp;required can be a&nbsp;significant&nbsp;barrier to&nbsp;larger studies. Dovetail&#39;s&nbsp;new products&nbsp;reduce the sequencing burden by&nbsp;over&nbsp;90%, enabling interactions between promoters and their regulatory elements to be studied at a fraction of the cost. In addition, the targeted approach increases&nbsp;the&nbsp;sensitivity and resolution of the assay. Taken together, these benefits make this approach ideal&nbsp;for a broad variety of research questions including&nbsp;larger&nbsp;translational studies, opening&nbsp;the potential for discovery of a new class of chromatin topology-based biomarker.&nbsp;
Emily&nbsp;Leproust,&nbsp;Ph.D., CEO and co-founder of Twist Bioscience,&nbsp;stated,&nbsp;&quot;We&nbsp;are&nbsp;thrilled to&nbsp;be collaborating with Dovetail&nbsp;Genomics&nbsp;to&nbsp;bring&nbsp;Twist&#39;s&nbsp;innovative&nbsp;targeted enrichment&nbsp;technology to new markets.&nbsp;With our incredibly flexible target enrichment design capabilities and precise DNA synthesis,&nbsp;Dovetail&nbsp;is developing&nbsp;new&nbsp;and innovative panels to advance&nbsp;the study of&nbsp;chromatin topology.&quot;&nbsp;
&quot;The ability of&nbsp;regulatory elements to act across large genomic distances has&nbsp;long&nbsp;been known and,&nbsp;through&nbsp;chromatin conformation capture&nbsp;techniques,&nbsp;the looping events that bring promoters and their regulatory elements, such as&nbsp;transcriptional enhancers,&nbsp;into close proximity&nbsp;are just starting to be probed,&quot; said Todd Dickinson, CEO. &quot;Our&nbsp;new panels&nbsp;now&nbsp;enable&nbsp;these experiments to be completed&nbsp;at a fraction of the cost of genome-wide Hi-C approaches.&nbsp;This&nbsp;opens up avenues&nbsp;for&nbsp;translational research&nbsp;that&nbsp;rely on&nbsp;larger sample cohorts.&nbsp;In working with Twist, we are confident&nbsp;that these new best-in-class tools&nbsp;will&nbsp;help to&nbsp;accelerate&nbsp;understanding of&nbsp;human&nbsp;disease mechanisms, aid in drug discovery programs&nbsp;and offer a&nbsp;novel&nbsp;and valuable&nbsp;class of biomarker&nbsp;benefiting&nbsp;human disease diagnosis and management.&quot;&nbsp;

TWST

Dovetail Genomics Announces New Capture Hi-C Targeted Enrichment Panels; Solution Incorporates Twist Bioscience's Targeted Enrichment Technology

BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.54) by 7.41 percent. This is unchanged from the same period last year.

Earnings

BYSI

BeyondSpring Q1 EPS $(0.58) Misses $(0.54) Estimate

On <a href="https://www.cnbc.com/video/2021/06/15/fast-pitch-why-you-should-buy-marvell.html">CNBC&#39;s &quot;Fast Money,&quot;</a> Shana Sissel of Spotlight Asset Group spoke about Marvell Technology Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvl#NASDAQ">MRVL</a>). For the past few years, the company changed its legacy business model through strategic acquisitions and smart business planning and it&#39;s now focusing on end-to-end technology solutions for cloud data centers and 5G infrastructure.
The stock has underperformed its peers over the last year, but the latest quarter included some positive signs, said Sissel. Marvell is trading at a discount to its peers like NVIDIA Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>), but it has a better balance sheet, less leverage and a much higher earnings growth, she added. She finds the stock attractive at its current price level.

Media

MRVL

NVDA

Why Spotlight Asset Group Is Bullish On Marvell Technology

<ul>
	<li>Sony Corp&nbsp;(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/sne#NYSE" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">SNE</a>)-owned Sony Pictures Home Entertainment&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/02/n19884025/sony-pictures-and-lionsgate-team-up-on-new-multi-year-physical-home-entertainment-distribution-agr" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">inked a multi-year distribution agreement</a>&nbsp;with&nbsp;Lions Gate Entertainment Corp&rsquo;s&nbsp;(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/lgf-b#NYSE" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">LGF-B</a>) to handle physical home entertainment releases in the U.S. and Canada.</li>
	<li>Lions Gate will continue to maintain its independent sales and marketing teams while leveraging Sony Pictures&rsquo; supply chain and distribution services.</li>
	<li>&ldquo;By working together, we can identify and leverage efficiencies in the supply chain that will benefit not only our respective studios, but also retailers, and ultimately, the millions of consumers who enjoy Sony Pictures and Lionsgate feature films and TV programs in the 4K UHD, Blu-ray and DVD formats,&rdquo; said Sony Pictures EVP Jason Spivak.</li>
	<li>&ldquo;This collaboration makes both our businesses even stronger, and our new agreement enhances our ability to serve the retail community and consumers with innovation, adaptability, and strong content slates in the years to come,&rdquo; said Lions Gate Motion President Ron Schwartz.</li>
	<li>Sony Pictures will begin to distribute Lionsgate physical home entertainment properties in July.</li>
	<li>Price action:&nbsp;SNE stock was down 0.78% at $106.24 on the last check Friday, LGF.B shares were up 0.04% at $12.44.</li>
</ul>

Tech

Sony Pictures Forms Multi-Year Partnership With Lions Gate Over Home Entertainment Distribution

LGF-B

LGF.B

Lions Gate Entertainment Corporation Class B Non-Voting Shares

Recent Quotes

Analyst Ratings

Related Companies

Lions Gate Entertainment Corporation Class B Non-Voting Shares Frequently Asked Questions

How do I buy Lions Gate Entertainment Corporation Class B Non-Voting Shares (LGF-B) stock?

Who are Lions Gate Entertainment Corporation Class B Non-Voting Shares's (LGF-B) competitors?

What is the target price for Lions Gate Entertainment Corporation Class B Non-Voting Shares (LGF-B) stock?

Current Stock Price for Lions Gate Entertainment Corporation Class B Non-Voting Shares (LGF-B)?

Does Lions Gate Entertainment Corporation Class B Non-Voting Shares (LGF-B) pay a dividend?

When is Lions Gate Entertainment Corporation Class B Non-Voting Shares (NYSE:LGF-B) reporting earnings?

Is Lions Gate Entertainment Corporation Class B Non-Voting Shares (LGF-B) going to split?

What sector and industry does Lions Gate Entertainment Corporation Class B Non-Voting Shares (LGF-B) operate in?